Lupin Ltd

BSE: LUPIN500257ISIN INE326A01037

Healthcare
Pharmaceuticals
BSE 100

Share price

₹2,015.00+3.00 (+0.15%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹2,530.00
52W low: ₹1,893.25
Off 52W high: -20.36%
1M return: +0.25%
3M return: -15.55%
6M return: -17.50%
1Y return: +0.84%
20D avg volume: 40,266
50 DMA: ₹2,051.34
200 DMA: ₹2,240.26

Key ratios Consolidated

Market cap: ₹92,145 Cr
Current price: ₹2,015.00
52W high / low: ₹2,530.00 / ₹1,893.25
Face value: ₹2.00
P/E: 17.65
P/B: 3.83
EPS (TTM): ₹114.18
Book value / share: ₹525.92
ROE: —
ROCE: 28.40%
Operating margin: —
Net margin: —
Debt / equity: 0.26
Net debt: ₹1,742 Cr
Interest cover: 16.82
Dividend yield: 0.89%
Dividend / share (TTM): ₹18.00
Payout: 15.76%
Cash conversion cycle: 111.1 days

Financials

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	7,827	8,277	7,475	7,168	7,048	6,268	5,667	5,768	5,673	5,600	4,961	5,197
	126.79	130.32	140.71	114.70	90.00	79.04	56.95	53.71	42.29	67.78	29.25	29.37
	7,954	8,407	7,615	7,282	7,138	6,347	5,724	5,821	5,715	5,668	4,990	5,227
	6,374	6,390	5,556	5,334	5,131	4,932	4,828	4,750	4,660	4,675	4,492	4,491
	1,311	1,312	1,231	1,125	1,139	1,127	1,109	1,084	1,118	1,146	1,094	1,107
	733.18	842.27	708.41	719.73	724.92	713.95	575.69	766.39	659.98	640.56	661.11	676.12
	1,424	1,383	1,243	1,143	1,106	1,083	1,001	984.39	1,008	971.04	900.22	889.24
	105.71	109.64	120.16	114.98	107.59	91.76	89.10	66.89	70.87	68.01	71.29	74.01
	485.90	452.85	446.79	312.96	316.77	298.98	393.18	271.45	256.92	247.71	457.10	257.20
	2,351	2,355	1,895	1,884	1,776	1,686	1,659	1,696	1,667	1,598	1,490	1,560
	1,580	2,017	2,059	1,949	2,007	1,416	895.84	1,071	1,055	993.03	497.71	736.10
	0.00	0.00	-131.34	-426.57	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	1,580	2,017	1,928	1,522	2,007	1,416	895.84	1,071	1,055	993.03	497.71	736.10
	424.30	600.38	459.33	341.53	522.14	194.08	113.46	212.41	195.38	187.49	129.49	117.40
	1,155	1,417	1,469	1,181	1,485	1,221	782.38	858.86	859.48	805.54	368.22	618.70
	25.27	30.95	31.96	25.74	32.36	26.70	16.93	18.75	18.70	17.58	7.89	13.47
Key metrics
	2,171	2,580	2,495	1,950	2,431	1,806	1,378	1,410	1,383	1,309	1,026	1,067
	27.70%	31.20%	33.40%	27.20%	34.50%	28.80%	24.30%	24.40%	24.40%	23.40%	20.70%	20.50%
	14.80%	17.10%	19.60%	16.50%	21.10%	19.50%	13.80%	14.90%	15.20%	14.40%	7.40%	11.90%
	6.20%	—	8.00%	—	9.30%	—	4.90%	—	—	—	—	—
	11.10%	32.00%	31.90%	24.30%	24.20%	11.90%	14.20%	11.00%	—	—	—	—
	-22.20%	16.00%	87.70%	37.50%	72.80%	51.60%	112.50%	38.80%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18
Income statement
	30,746	27,958	22,708	20,011	16,642	16,405	15,163	15,375	16,718	15,804
	512.52	424.45	195.82	120.17	73.36	141.69	136.29	483.76	364.02	150.35
	31,259	28,382	22,904	20,131	16,715	16,547	15,299	15,859	17,082	15,954
	23,654	20,952	18,889	17,709	15,999	17,920	13,624	14,353	15,229	13,947
	4,979	4,622	4,457	4,142	3,688	3,236	3,170	3,164	3,560	2,955
	3,004	2,867	2,643	2,959	2,938	3,444	2,677	2,258	2,460	2,156
	5,193	4,575	3,964	3,495	3,087	2,989	2,826	2,987	3,151	2,865
	450.49	434.49	294.87	311.61	274.30	142.77	140.64	362.98	307.83	204.35
	1,698	1,376	1,169	1,197	880.69	1,659	887.41	970.22	1,085	—
	8,485	7,241	6,618	6,073	5,054	4,838	4,408	4,603	4,839	4,518
	7,605	7,430	4,015	2,422	716.49	-1,373	1,675	1,505	1,853	2,008
	-557.91	-557.91	0.00	0.00	0.00	0.00	0.00	-752.07	-339.98	-1,464
	7,047	6,873	4,015	2,422	716.49	-1,373	1,675	753.29	1,513	543.29
	1,826	1,517	708.74	486.70	268.80	137.15	448.52	1,157	901.69	288.46
	5,221	5,355	3,306	1,936	447.69	-1,509	1,228	-269.78	615.48	258.35
	113.92	116.75	71.95	42.05	9.46	-33.65	27.09	-8.83	—	—
Key metrics
	9,196	8,683	5,479	3,931	1,871	428.91	2,703	2,086	2,906	747.64
	29.91%	31.10%	24.10%	19.60%	11.20%	2.60%	17.80%	13.60%	17.40%	4.70%
	16.98%	19.20%	14.60%	9.70%	2.70%	-9.20%	8.10%	-1.80%	3.70%	1.60%
	—	28.40%	21.30%	—	—	—	—	—	—	—
	24.22%	23.10%	13.50%	20.20%	1.40%	8.20%	-1.40%	-8.00%	5.80%	—
	20.10%	62.00%	70.80%	332.30%	129.70%	-222.90%	555.20%	-143.80%	138.20%	—
	—	5,491	-1,252	—	—	—	—	—	—	—
	—	1.41	0.13	—	—	—	—	—	—	—
	—	0.26	0.29	—	—	—	—	—	—	—
	—	1,742	3,533	—	—	—	—	—	—	—
	—	111.1	128.9	—	—	—	—	—	—	—
Balance sheet
	—	38,365	29,205	—	—	—	—	—	—	—
	—	24,027	16,799	—	—	—	—	—	—	—
	—	4,168	1,544	—	—	—	—	—	—	—
	—	6,604	5,497	—	—	—	—	—	—	—
	—	6,083	5,476	—	—	—	—	—	—	—
	—	1,543	1,252	—	—	—	—	—	—	—
	—	5,449	5,148	—	—	—	—	—	—	—
	—	4,173	2,958	—	—	—	—	—	—	—
	—	12,651	8,961	—	—	—	—	—	—	—
	—	5,910	5,077	—	—	—	—	—	—	—
	—	4,267	3,310	—	—	—	—	—	—	—
	—	1,643	1,766	—	—	—	—	—	—	—
	—	22,513	17,294	—	—	—	—	—	—	—
Cash flow
	—	7,546	429.94	—	—	—	—	—	—	—
	—	-4,076	-1,602	—	—	—	—	—	—	—
	—	-845.87	1,732	—	—	—	—	—	—	—
	—	2,055	1,682	—	—	—	—	—	—	—

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	3,567	7,172	5,235	4,501	4,068	5,709	4,486	4,208	4,106	4,168	3,396	4,116
	95.52	102.48	88.83	99.80	70.00	54.14	48.79	55.30	32.62	38.22	31.34	23.16
	3,663	7,274	5,323	4,601	4,138	5,763	4,534	4,263	4,139	4,206	3,427	4,139
	3,582	3,664	3,169	3,099	3,095	3,175	2,981	2,969	3,155	3,123	2,999	3,055
	1,014	1,051	995.53	909.55	864.14	909.14	923.60	912.78	907.04	973.30	884.81	836.97
	338.86	308.90	274.58	296.13	309.68	311.93	277.74	331.27	312.43	325.41	344.56	364.47
	746.98	719.69	660.65	631.51	608.83	643.89	552.42	576.37	594.51	588.77	517.07	522.47
	32.55	35.56	38.77	36.02	27.78	18.90	33.85	19.55	17.55	13.55	13.49	11.36
	193.12	190.01	177.05	178.68	174.72	176.73	207.98	152.52	145.77	141.42	290.04	145.18
	1,337	1,370	1,056	1,065	1,015	1,154	1,011	1,120	1,089	1,116	966.65	1,037
	81.12	3,610	2,155	1,502	1,043	2,588	1,553	1,294	984.05	1,083	428.16	1,084
	-76.93	0.00	447.73	-633.84	592.68	0.00	0.00	-77.22	—	—	—	—
	4.19	3,610	2,602	867.94	1,636	2,588	1,553	1,217	984.05	1,083	428.16	1,084
	10.10	895.46	438.66	150.49	278.46	460.08	261.74	232.39	176.29	193.74	44.08	167.52
	-5.91	2,715	2,164	717.45	1,357	2,128	1,291	984.67	807.76	889.18	384.08	916.44
	-0.13	59.37	47.35	15.71	29.72	46.60	28.30	21.58	17.71	19.51	8.43	20.14
Key metrics
	229.86	3,836	2,818	1,083	1,838	2,784	1,795	1,389	1,147	1,238	731.69	1,240
	6.40%	53.50%	53.80%	24.10%	45.20%	48.80%	40.00%	33.00%	27.90%	29.70%	21.50%	30.10%
	-0.20%	37.90%	41.30%	15.90%	33.40%	37.30%	28.80%	23.40%	19.70%	21.30%	11.30%	22.30%
	0.10%	—	8.40%	—	5.90%	—	6.30%	—	—	—	—	—
	-12.30%	25.60%	16.70%	7.00%	-0.90%	37.00%	32.10%	2.20%	—	—	—	—
	-100.40%	27.60%	67.60%	-27.10%	68.00%	139.30%	236.20%	7.40%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18
Income statement
	20,475	19,513	16,968	14,666	11,259	11,772	11,056	11,026	11,356	10,088
	386.63	312.77	174.05	106.73	91.26	150.42	129.09	475.19	291.34	131.12
	20,862	19,825	17,142	14,773	11,350	11,922	11,185	11,501	11,648	10,219
	13,514	12,538	12,227	11,989	10,823	12,084	9,555	9,689	8,965	8,425
	3,970	3,678	3,717	3,407	3,151	2,817	2,741	2,753	2,693	2,260
	1,218	1,192	1,247	1,634	1,526	1,893	1,523	1,483	1,347	1,130
	2,759	2,545	2,312	2,096	1,934	1,918	1,696	1,703	1,515	1,442
	142.90	121.47	84.50	56.35	98.44	73.47	40.62	52.59	35.47	33.24
	738.86	707.18	647.69	724.75	548.34	514.19	502.83	518.75	426.30	389.81
	4,827	4,289	4,258	4,095	3,563	3,299	3,134	3,208	3,095	3,086
	7,348	7,288	4,914	2,785	527.14	-161.53	1,630	1,811	2,682	1,794
	-263.04	406.57	-77.22	—	—	—	—	-759.21	-339.98	—
	7,085	7,694	4,837	2,785	527.14	-161.53	1,630	1,052	2,342	1,794
	1,495	1,328	864.16	458.60	101.93	27.17	371.08	324.70	803.54	449.27
	5,590	6,367	3,973	2,326	425.21	-188.70	1,259	727.55	1,539	1,345
	122.30	139.38	87.10	51.10	9.35	-4.16	27.77	16.07	—	—
Key metrics
	7,966	8,523	5,569	3,566	1,174	426.13	2,173	1,624	2,804	2,217
	38.91%	43.70%	32.80%	24.30%	10.40%	3.60%	19.70%	14.70%	24.70%	22.00%
	27.30%	32.60%	23.40%	15.90%	3.80%	-1.60%	11.40%	6.60%	13.60%	13.30%
	—	25.00%	19.50%	—	—	—	—	—	—	—
	10.85%	15.00%	15.70%	30.30%	-4.40%	6.50%	0.30%	-2.90%	12.60%	—
	-2.98%	60.20%	70.80%	447.00%	325.30%	-115.00%	73.00%	-52.70%	14.40%	—
	—	4,823	1,150	—	—	—	—	—	—	—
	—	0.87	0.62	—	—	—	—	—	—	—
	—	0.02	0.01	—	—	—	—	—	—	—
	—	465.25	-115.96	—	—	—	—	—	—	—
	—	144.9	148.8	—	—	—	—	—	—	—
Balance sheet
	—	36,103	28,432	—	—	—	—	—	—	—
	—	15,595	11,895	—	—	—	—	—	—	—
	—	111.63	341.80	—	—	—	—	—	—	—
	—	6,922	5,664	—	—	—	—	—	—	—
	—	3,351	3,227	—	—	—	—	—	—	—
	—	1,026	1,114	—	—	—	—	—	—	—
	—	3,169	3,446	—	—	—	—	—	—	—
	—	2,529	1,969	—	—	—	—	—	—	—
	—	4,832	3,233	—	—	—	—	—	—	—
	—	576.88	225.84	—	—	—	—	—	—	—
	—	576.88	0.00	—	—	—	—	—	—	—
	—	0.00	225.84	—	—	—	—	—	—	—
	—	30,134	24,278	—	—	—	—	—	—	—
Cash flow
	—	5,540	2,445	—	—	—	—	—	—	—
	—	-5,649	-1,766	—	—	—	—	—	—	—
	—	-121.13	-460.23	—	—	—	—	—	—	—
	—	717.04	1,294	—	—	—	—	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +20.12%
Sales CAGR 5Y: +12.03%
Profit CAGR 3Y: +146.47%
Profit CAGR 5Y: +38.29%
Sales YoY (TTM): +10.85%
Profit YoY (TTM): -2.98%

Consolidated

Sales CAGR 3Y: +18.88%
Sales CAGR 5Y: +13.02%
Profit CAGR 3Y: +128.70%
Profit CAGR 5Y: +34.25%
Sales YoY (TTM): +24.22%
Profit YoY (TTM): +20.10%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 46.85%

Quarter	September 2026	June 2026
Promoter %	46.85%	46.85%

Holder	Type	Holding	Previous	Change
Lupin Investments Private Limited	Promoter	45.31%	45.31%	0.00%
HDFC Mutual Fund-HDFC Arbitrage Fund	Public	4.68%	—	—
LICI New Pension Plus Growth Fund	Public	3.90%	—	—
NPS Trust- A/C ICICI Pension Fund Scheme E - Tier I	Public	2.63%	—	—
Nippon Life India Trustee Ltd- A/C Nippon India Growth Mid Cap Fund	Public	2.33%	2.60%	-0.27%
Mirae Asset BSE LARGEMID (60:40) Stable Dividend 50 ETF	Public	1.88%	—	—
Sbi Arbitrage Fund	Public	1.13%	—	—
Manju D Gupta	Promoter	0.85%	0.85%	0.00%
Nilesh Gupta	Promoter	0.20%	0.20%	0.00%
Anuja Gupta	Promoter	0.16%	0.16%	0.00%
D B Gupta HUF (Nilesh Deshbandhu Gupta, Karta of HUF)	Promoter	0.14%	0.14%	0.00%
Vinita Gupta	Promoter	0.07%	0.07%	0.00%
Richa Gupta	Promoter	0.05%	0.05%	0.00%
Kavita Gupta	Promoter	0.04%	0.04%	0.00%
Veda Nilesh Gupta	Promoter	0.02%	0.02%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%

Filings & corporate actions

Recent announcements

Link of Audio recording of the Earnings Call-Q2 FY27.4 Nov 2026 · Company Update / Analyst / Investor Meet
Investor Presentation- Q2 FY20274 Nov 2026 · Company Update / Investor Presentation
Lupin Q2 FY2027 Results4 Nov 2026 · Company Update / Press Release / Media Release
Appointment of Mr. Akhil Gupta as an Additional Director (Non-Executive, Independent) effective November 03, 2026 and as an Independent Director for a term of five consecutive years with ....4 Nov 2026 · Company Update / Change in Directorate
Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026.4 Nov 2026 · Result / Financial Results
Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026.4 Nov 2026 · Board Meeting / Outcome of Board Meeting
Lupin Launches Raltegravir Tablets, USP, 600 mg in the United States.3 Nov 2026 · Company Update / Press Release / Media Release
Lupin Receives U.S. FDA Approval for Amifampridine Tablets.2 Nov 2026 · Company Update / Press Release / Media Release
U.S. FDA has concluded an inspection at Company''s manufacturing facility located in Goa, India.24 Oct 2026 · Company Update / General
Intimation of allotment of 3,033 equity shares under ESOP.23 Oct 2026 · Company Update / Allotment of ESOP / ESPS
Lupin Appoints Brian Savage as President, Chief Legal Officer.23 Oct 2026 · Company Update / Press Release / Media Release
Intimation about the Appointment of Senior Management Personnel.22 Oct 2026 · Company Update / Change in Management
Intimation regarding Grant of 40,157 Stock Options under Lupin Employees Stock Option Scheme 2025.19 Oct 2026 · Company Update / Allotment of ESOP / ESPS
Schedule of Earnings Call for Q2 FY2719 Oct 2026 · Company Update / Analyst / Investor Meet
Lupin Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve the Unaudited Standalone and Consolidated ....19 Oct 2026 · Board Meeting / Board Meeting
ESG Rating by NSE Sustainability Ratings and Analytics Limited.15 Oct 2026 · Company Update / General
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended on September 30, 2026.9 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Lupin Receives U.S. FDA Approval for Phytonadione Injectable Emulsion, USP8 Oct 2026 · Company Update / Press Release / Media Release
Lupin Launches Formoflo-G MDI, World''s First Fixed-dose Triple Combination Drug for COPD Management.6 Oct 2026 · Company Update / Press Release / Media Release
Multicare Pharmaceuticals Philippines, Inc. (MPPI) has completed buyback of 30,559 shares, pursuant to which MPPI has become a step-down wholly owned subsidiary of the Company effective ....1 Oct 2026 · Company Update / General
Intimation of Closure of Trading Window.28 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Lupin Receives Tentative Approval from U.S. FDA for Novel Apixaban Oral Suspension.28 Sep 2026 · Company Update / Press Release / Media Release
Intimation of allotment of 24,111 equity shares under ESOP.21 Sep 2026 · Company Update / Allotment of ESOP / ESPS
Intimation about participating in the Analyst/Institutional Investors Meet.8 Sep 2026 · Company Update / Analyst / Investor Meet
Lupin Receives U.S. FDA Approval for Modafinil Tablets, USP.4 Sep 2026 · Company Update / Press Release / Media Release
ESG Rating by Crisil ESG Ratings & Analytics Ltd.28 Aug 2026 · Company Update / General
Intimation of allotment of 30967 equity shares under ESOP.25 Aug 2026 · Company Update / Allotment of ESOP / ESPS
ESG Rating by ESG Risk Assessment and Insights Limited.24 Aug 2026 · Company Update / General
VISUfarma B.V., the Netherlands, a wholly owned subsidiary of the Company, has entered into an Exclusive License Agreement with Visus Therapeutics, Inc. U.S.A.20 Aug 2026 · Company Update / General
Intimation of Demise of Dr. Sofia Mumtaz, President, Legal & Compliance, Canada, ANZ & NEA Business, a Senior Management Personnel of the Company.18 Aug 2026 · Company Update / Demise
Lupin Announces Approval from U.S. FDA for Pitolisant Tablets.17 Aug 2026 · Company Update / Press Release / Media Release
Transcript of Q1 FY2027 Earnings Conference Call12 Aug 2026 · Company Update / Earnings Call Transcript
Lupin Announces the Approval of Sodium Zirconium Cyclosilicate for Oral Suspension in the United States.10 Aug 2026 · Company Update / Press Release / Media Release
Intimation about participating in the Analyst/Institutional Investors Meet.10 Aug 2026 · Company Update / Analyst / Investor Meet
Copies of Newspaper publication in respect of Unaudited Financial Results of the Company for the quarter ended June 30, 2026.8 Aug 2026 · Company Update / Newspaper Publication
Link of Audio recording of the Earnings Call-Q1 FY27.7 Aug 2026 · Company Update / Analyst / Investor Meet
Investor Presentation (Revised) - Q1 FY27 Results7 Aug 2026 · Company Update / Investor Presentation
Investor Presentation- Q1 FY20276 Aug 2026 · Company Update / Investor Presentation
Lupin Q1 FY2027 Results6 Aug 2026 · Company Update / Press Release / Media Release
Board Meeting Outcome for Approval of the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026.6 Aug 2026 · Result / Financial Results

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 18.0000	17 Jul 2026	17 Jul 2026	—
Final Dividend - Rs. - 12.0000	25 Jul 2025	25 Jul 2025	—
Final Dividend - Rs. - 8.0000	16 Jul 2024	16 Jul 2024	—

Board meetings

3 Nov 2026 Board Meeting - Financial Results
6 Aug 2026 Board Meeting - Financial Results